Nephrogenic diabetes insipidus due to a new mutation of the arginine vasopressin V2 receptor gene in a girl presenting with non-accidental injury

Measurement of arginine vasopressin

Arginine vasopressin (AVP) is a peptide hormone synthesised in the hypothalamus and secreted from nerve terminals within the posterior pituitary gland. Secretion is primarily under osmoregulatory control and levels rise in plasma in response to a body water deficit and are suppressed in response to water overload. The responsive end organ in osmoregulation is the kidney, and an increase in plasma AVP normally results in urine concentration while a decrease results in urine dilution and a diuresis. The hormone is present in urine. The level of AVP in urine is directly related to the prevailing plasma concentration, but is also influenced by urine concentration, osmolal clearance, and renal metabolism. The measurement of AVP in plasma and urine is by radioimmunoassay (RIA). Prior extraction of the hormone is required to remove interfering substances and, particularly for plasma measurements, to concentrate the assayed sample. The secretion of AVP by the posterior pituitary gland is also stimulated by non-osmoregulatory factors such as reduced blood volume, reduced blood pressure, and nausea and is acutely suppressed by an oropharyngeal reflex. Plasma AVP measurement has a role in delineating complex osmoregulatory dysfunction, but protocols for study need to control the non-osmoregulated stimulatory and inhibitory factors. The urine AVP excretion rate corrected for osmolal clearance has a role in the assessment of renal responsiveness to its action.

AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance

Almost 90% of nephrogenic diabetes insipidus (NDI) is due to mutations in the arginine-vasopressin receptor 2 gene (AVPR2). We retrospectively examined all the published mutations/variants in AVPR2. We planned to perform a comprehensive review of all the AVPR2 mutations/variants and to test whether any amino acid change causing a missense mutation is significantly more or less common than others. We performed a Medline search and collected detailed information regarding all AVPR2 mutations and variants. We performed a frequency comparison between mutated and wild-type amino acids and codons. We predicted the mutation effect or reported it based on published in vitro studies. We also reported the ethnicity of each mutation/variant carrier. In summary, we identified 211 AVPR2 mutations which cause NDI in 326 families and 21 variants which do not cause NDI in 71 NDI families. We described 15 different types of mutations including missense, frameshift, inframe deletion, deletion, insertion, nonsense, duplication, splicing and combined mutations. The missense mutations represent the 55.83% of all the NDI published families. Arginine and tyrosine are significantly (P = 4.07E-08 and P = 3.27E-04, respectively) the AVPR2 most commonly mutated amino acids. Alanine and glutamate are significantly (P = 0.009 and P = 0.019, respectively) the least mutated AVPR2 amino acids. The spectrum of mutations varies from rare gene variants or polymorphisms not causing NDI to rare mutations causing NDI, among which arginine and tyrosine are the most common missense. The AVPR2 mutations are spread world-wide. Our study may serve as an updated review, comprehensive of all AVPR2 variants and specific gene locations. J. Cell. Physiol. 217: 605-617, 2008. (c) 2008 Wiley-Liss, Inc.